Brenda Cooper is an Oncology physician. ClinicalTrials.gov lists 16 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11100 Euclid Ave
Cleveland, OH 441061716
Telephone
216-844-8500Provider last certified this registry record 13 Dec 2020.
Clinical trials
- Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT
Sponsor: Case Comprehensive Cancer Center
- Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Sponsor: Case Comprehensive Cancer Center
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sponsor: Case Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20252 payments
- ABBVIE INC.Program year20252 payments
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
51.6%Kinase inhibitor28%Brukinsa24%Calquence21%Imatinib Mesylate19%Imbruvica17%Jakafi9%Sprycel8%Tasigna3%Part D<11 patientsThalidomide Analog15.3%Lenalidomide53%Revlimid26%Pomalyst21%Part D<11 patients+ 3 more classes in this area
Dermatology
12.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.3%Acyclovir100%Part D≥67 patientsMetabolism & gastrointestinal
11%Proton pump inhibitor3%Pantoprazole Sodium75%Omeprazole26%Part D<11 patientsSerotonin-3 Receptor Antagonist2.7%Ondansetron Hcl100%Part D≥25 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1997–2006 per NIH RePORTER. The latest:
- MECHANISM BASED PHASE I TRIAL OF TOPOTECAN IN LEUKEMIA
Case Western Reserve University
FY2000$153,000R21CA081500
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”